MyMD Pharmaceuticals, Inc. MYMD Stock (” MyMD” or “the Firm”), a medical stage pharmaceutical company committed to extending healthy life expectancy, today introduced that the initial client has been enrolled in the Business’s Phase 2 medical test of lead candidate MYMD-1, an oral immune regulator drug, as a therapy for postponing aging and also increasing healthy and balanced life-span.
The primary endpoint for the Stage 2 double-blind, placebo-controlled medical test is to attain a reduction in the flowing levels of (TNF-α), lump death aspect receptor I (TNFRI) and also IL-6. TNF-α and IL-6 are the proteins in the body that cause inflammation and also aid turn on the procedure of aging. The additional measures of the trial will certainly be the safety, tolerability, and also pharmacokinetics in this population of individuals.
” In a Stage 1 scientific test of MYMD-1, we showed the drug’s statistically significant efficacy in lowering levels of TNF-α, a key player in causing pathological aging, in the blood. The FDA has approved TNF-α reduction as the key endpoint for our Phase 2 research, which we believe positions us well for an effective Stage 2 result,” stated Chris Chapman, M.D., President, Director and Principal Medical Officer of MyMD. “The initiation of individual registration in this study advances our mission to reduce the aging procedure, avoid loss of muscle tissue in aging, limitation frailty, and extend healthy life-span.”
MyMD has stated that there are no FDA-approved drugs for treating aging disorders and prolonging healthy and balanced lifespan people, a market anticipated to be a minimum of $600 billion by 20251 according to a major financial investment financial institution. TNF-α blockers are the most prescribed medicines by income, a global market of roughly $40 billion annually,2 as well as, according to Nature Aging journal,3 a stagnation in aging that would certainly boost life span by one year is worth $38 trillion and by one decade is worth $367 trillion.
Along with aging, MYMD-1’s unique activity in controling the body immune system as well as treating chronic inflammation is being created for the therapy of autoimmune condition, consisting of rheumatoid joint inflammation (RA), numerous sclerosis (MS), diabetes mellitus, as well as inflammatory digestive tract illness.
” We intend to start creating protocols for a Phase 2 pilot study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman noted. “The increasing prevalence of rheumatoid arthritis and other autoimmune and also inflammatory illness are driving need for TNF preventions like MYMD-1, as well as our team believe our by mouth provided medicine with extremely low poisoning would be disruptive to the $60 billion market for RA if accepted by the FDA for this indicator.”
Rheumatoid joint inflammation influences roughly 40 million people globally.4.
Initially created for autoimmune illness, MYMD-1’s key objective is to slow the aging procedure, protect against sarcopenia as well as frailty, as well as prolong healthy lifespan. Due to the fact that it can cross the blood-brain barrier as well as access to the main nervous system (CNS), MYMD-1 is likewise positioned to be a feasible therapy for brain-related conditions. Its device of activity and also efficiency in illness including multiple sclerosis (MS) and thyroiditis have been studied through collaborations with numerous scholastic institutions. MYMD-1 is likewise showing pledge in pre-clinical studies as a prospective therapy for blog post- COVID-19 difficulties and also as an anti-fibrotic and also anti-proliferation therapeutic.
MYMD-1 has actually shown efficiency in pre-clinical researches in managing the body immune system by executing as a discerning inhibitor of lump death factor-alpha (TNF-α), a motorist of persistent inflammation. Unlike various other treatments, MYMD-1 has been received these pre-clinical researches to precisely obstruct TNF-α when it ends up being overactivated in autoimmune diseases and cytokine tornados, however not block it from doing its typical task of being a first -responder to any regular type of modest infection. MYMD-1’s convenience of dental dosing is an additional differentiator compared to currently available TNF-α blockers, every one of which need shipment by injection or mixture. No accepted TNF inhibitor has ever before been dosed by mouth. In addition, the medication is not immunosuppressive and also has actually not been shown to create the significant negative effects common with typical treatments that treat inflammation.
About MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a medical phase pharmaceutical company devoted to extending healthy lifespan, is concentrated on developing two unique healing platforms that treat the causes of condition rather than just dealing with the signs. MYMD-1 is a drug platform based upon a scientific stage little particle that controls the body immune system to manage TNF-α, which drives chronic inflammation, as well as various other pro-inflammatory cell signaling cytokines. MYMD-1 is being established to delay aging, increase long life, as well as deal with autoimmune diseases and also COVID-19- linked depression. The Firm’s 2nd medicine platform, Supera-CBD, is being developed to deal with persistent discomfort, dependency and also epilepsy. Supera-CBD is a novel synthetic by-product of cannabidiol (CBD) as well as is being created to resolve as well as improve upon the quickly expanding CBD market, that includes both FDA accepted medications as well as CBD products not presently controlled as medicines. For more details, check out www.mymd.com.